



Aerpio Pharmaceuticals to Present at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC

August 30, 2018

CINCINNATI--(BUSINESS WIRE)--Aug. 30, 2018-- Aerpio Pharmaceuticals, Inc. (Nasdaq:ARPO), a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, today announced that Chief Executive Officer, Stephen Hoffman, M.D., Ph.D., will present at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC, on Thursday, September 6, 2018 at 10:00 a.m. Eastern Time in New York, NY. Dr. Hoffman will provide a corporate overview and business update.

The presentation will be webcast live and may be accessed by visiting Aerpio's website at <http://ir.aerpio.com/>.

About Aerpio Pharmaceuticals

Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases. The Company's lead compound, AKB-9778, is a small molecule activator of the Tie2 pathway and is in clinical development for the treatment of non-proliferative diabetic retinopathy. For more information, please visit www.aerpio.com.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20180830005087/en/>

Source: Aerpio Pharmaceuticals, Inc.

Investor & Media:

Aerpio Pharmaceuticals, Inc.

Michael Rogers

Chief Financial Officer

mrogers@aerpio.com

or

Burns McClellan, on behalf of Aerpio Pharmaceuticals, Inc.

Media:

Robert Flamm, Ph.D.

rflamm@burnsmc.com

or

Investors:

Ami Bavishi

abavishi@burnsmc.com